Abstract
Objective:
To critically evaluate and elucidate optimised, multimodal prevention strategies for postoperative nausea and vomiting (PONV) in metabolic and bariatric surgery patients within an Enhanced Recovery After Surgery (ERAS) framework.
Data Sources:
Clinical databases including the Swedish Perioperative Registry, extensive scoping reviews, and randomised controlled trials evaluating perioperative bariatric interventions.
Review Methods:
A comprehensive synthesis of empirical data was conducted to evaluate the efficacy of intraoperative anaesthesia choices, opioid-sparing analgesia, regional fascial plane blocks, and multimodal pharmacological antiemetics.
Results:
PONV affects 30%–80% of bariatric patients. Female sex, younger age, and laparoscopic sleeve gastrectomy are profound independent risk factors. Evidence strongly supports abandoning volatile anaesthetics in favour of propofol-based total intravenous anaesthesia (TIVA). Opioid-free anaesthesia utilising dexmedetomidine, lidocaine, and regional blocks (e.g., Transversus Abdominis Plane blocks) significantly mitigates PONV incidence compared to opioid-based regimens. Single-agent prophylaxis is unequivocally insufficient; a multi-receptor approach combining a neurokinin-1 receptor antagonist (e.g., aprepitant) with a 5-HT3 antagonist, a corticosteroid, and a dopamine/histamine antagonist provides the most efficacious pharmacological shield.
Conclusion:
Effective PONV prevention in bariatric surgery demands a universal, multimodal ERAS approach. Clinicians must prioritise TIVA, strict opioid-sparing techniques, and combined multi-receptor pharmacological blockade to accelerate recovery and minimise complications.
Keywords
Clinical Messages
Bariatric surgery patients require a proactive, multimodal approach to PONV prevention; single-agent prophylaxis is clinically insufficient to suppress the emetic reflex in this high-risk demographic.
Volatile anaesthetics and systemic opioids are major modifiable triggers for PONV; utilising propofol-based total intravenous anaesthesia alongside opioid-free or opioid-sparing regional analgesic techniques significantly improves outcomes.
A targeted, multi-receptor pharmacological shield—ideally combining an NK-1 receptor antagonist, a 5-HT3 antagonist, a corticosteroid, and a D2 or H1 antagonist—is highly recommended to safeguard surgical recovery.
Introduction
Metabolic and bariatric surgery currently represents the most efficacious and durable intervention for the management of morbid obesity and the resolution of its associated metabolic syndrome comorbidities. The global proliferation of minimally invasive surgical techniques, predominantly laparoscopic sleeve gastrectomy and laparoscopic Roux-en-Y gastric bypass, has revolutionised the treatment paradigm for this high-risk demographic. Concurrently, the implementation of Enhanced Recovery After Surgery (ERAS) protocols has standardised perioperative care, aiming to attenuate the surgical stress response, accelerate physiological recovery, minimise hospital length of stay, and facilitate early mobilisation and oral intake. Despite these profound advancements in both surgical technique and anaesthetic management, the perioperative phase remains heavily encumbered by complications that directly antagonise the objectives of enhanced recovery. Among these challenges, postoperative nausea and vomiting (PONV) stands as the most prevalent, distressing, and clinically disruptive complication, affecting between 30% and 80% of patients undergoing bariatric procedures.[1]
The clinical and physiological ramifications of unmanaged PONV extend significantly beyond subjective patient discomfort and temporary dissatisfaction. In the immediate postoperative period, protracted emesis can rapidly induce severe dehydration, critical electrolyte derangements, and acute haemodynamic instability.[1]
Furthermore, the intense mechanical stress and violent diaphragmatic excursions associated with retching exert immense pressure on newly fashioned gastrointestinal anastomoses and staple lines. This sudden elevation in intra-abdominal and intragastric pressure precipitates a markedly heightened risk of catastrophic anastomotic leak, staple line disruption, wound dehiscence, venous hypertension, and postoperative haemorrhagic events.[1] From a broader healthcare utilisation perspective, persistent nausea and vomiting are identified as a primary driver of delayed discharge from the post-anaesthesia care unit (PACU), prolonged overall hospitalisation, and an increased rate of unplanned 30-day readmissions, all of which impose a substantial economic burden on healthcare infrastructures.[1]
The pathophysiology of PONV in the morbidly obese population is distinctly complex, representing a multifaceted interplay between unique neurohormonal profiles, altered gastrointestinal anatomy, and the specific pharmacokinetic behaviours of anaesthetic agents. Patients presenting with metabolic syndrome exhibit characteristic physiological deviations, including systemic low-grade inflammation, profound insulin resistance, hyperinsulinemia, and chronic hyperglycaemia.[2] These metabolic derangements inherently induce autonomic neuropathy and alter normal gastrointestinal motility, leading to delayed gastric emptying, increased visceral sensitivity, and a predisposition to gastro-oesophageal reflux.[2] Furthermore, the surgical alterations inherent to bariatric procedures drastically disrupt local neurohormonal signalling. The creation of a high-pressure, low-compliance gastric sleeve, or the rerouting of the alimentary limb in a gastric bypass, subjects the gastrointestinal tract to profound mechanical trauma and ischaemia. This surgical insult stimulates the release of highly emetogenic inflammatory mediators, such as serotonin, from enterochromaffin cells in the gut mucosa, which subsequently activate vagal afferent fibres projecting directly to the medullary vomiting centres.[2]
Compounding these anatomical and endocrinological vulnerabilities are the distinct pharmacological challenges associated with anaesthetising the morbidly obese patient. The excessive accumulation of adipose tissue significantly alters the volume of distribution for highly lipophilic anaesthetic agents, leading to prolonged accumulation, delayed clearance, and an extended window of central nervous system stimulation post-extubation.[3] When these factors are coupled with the routine perioperative administration of systemic opioids—which directly stimulate mu-opioid receptors in the chemoreceptor trigger zone located in the area postrema—the central and peripheral emetic pathways become overwhelmingly activated.[3]
The Fifth Consensus Guidelines for the Management of PONV advocate for reducing baseline risk through multimodal analgesia, regional anaesthesia, and propofol infusions while actively avoiding volatile anaesthetics.[4] Given the profound limitations and established failure rates of traditional, single-agent antiemetic regimens in this specific surgical population, contemporary ERAS guidelines unequivocally advocate for a comprehensive, multimodal approach to prophylaxis.[3] This optimised strategy requires a paradigm shift away from reactive treatment toward proactive, multi-receptor blockade. It encompasses rigorous preoperative risk stratification, the optimisation of intraoperative anaesthetic depth and agent selection, the aggressive implementation of opioid-sparing or completely opioid-free anaesthesia, the utilisation of targeted regional fascial plane blocks, the synergistic administration of multi-class pharmacological antiemetics, and the careful modulation of early postoperative dietary and fluid interventions.[3]
The primary objective of this comprehensive research article is to critically evaluate current empirical evidence and elucidate optimised prevention strategies for PONV, specifically tailored to the unique physiological demands of patients undergoing metabolic and bariatric surgery within an ERAS framework. By systematically synthesising large-scale national registry data, extensive scoping reviews of randomised controlled trials, and targeted prospective clinical evaluations, this analysis aims to decode the independent and synergistic effects of various prophylactic modalities. Ultimately, the goal is to construct an evidence-based, multimodal antiemetic blueprint that seamlessly integrates into existing clinical pathways, thereby systematically minimising the incidence of postoperative nausea, reducing the reliance on rescue therapeutics, accelerating the resumption of oral intake, and fulfilling the core mandates of enhanced recovery in bariatric surgery.[1]
Methods
To construct a scientifically rigorous and highly granular analytical framework, this article synthesises quantitative and qualitative data extracted from a diverse array of high-fidelity clinical databases, prospective interventional trials, and extensive scoping reviews specifically focusing on bariatric surgical populations and metabolic syndrome cohorts.
First, a comprehensive analysis of prospectively collected, population-level data from the Swedish Perioperative Registry was utilised to establish an epidemiological baseline. This dataset encompasses 8,426 adult patients who underwent elective laparoscopic Roux-en-Y gastric bypass or laparoscopic sleeve gastrectomy across 32 discrete hospital systems over a multi-year period.[5] This massive registry data provided a macroscopic, real-world view of early PONV incidence specifically within the PACU setting, allowing for the rigorous identification and multivariate logistic regression of fundamental demographic, procedural, and institutional risk factors.[5]
Second, an exhaustive scoping review encompassing 81 randomised controlled trials was analysed.[3] This review meticulously evaluated a broad spectrum of perioperative interventions targeted at mitigating PONV in laparoscopic bariatric surgery, specifically comparing volatile inhalational agents against total intravenous anaesthesia (TIVA), neuromuscular blockade reversal agents, and the integration of myriad opioid-sparing pharmacological adjuvants and regional anaesthesia techniques.[3]
Third, clinical outcomes derived from a targeted prospective evaluation conducted at Tashkent State Medical University were integrated. This trial involved 120 patients with morbid obesity (mean body mass index of 45.1 kg/m2) and evaluated the specific efficacy of a triple-component pharmacological antiemetic regimen (dexamethasone, ondansetron, and droperidol) combined with opioid-free postoperative analgesia, tracking temporal PONV incidence over 24 hours.[6] Similarly, findings from a randomised controlled trial isolating 120 bariatric patients carrying a formalised diagnosis of metabolic syndrome were incorporated.[2] This study stratified prophylactic interventions into standard care, dual therapy, triple therapy integrating the neurokinin-1 (NK-1) receptor antagonist aprepitant, and a comprehensive multimodal pathway.[2]
Finally, a prospective, unblinded randomised controlled trial involving 112 patients was examined to evaluate the physiological impact of early postoperative diet composition (high-protein full-liquid diet versus a standard clear liquid diet) within the enhanced recovery pathway following primary laparoscopic sleeve gastrectomy.[7]
Results
Epidemiology and Risk Stratification
Data extracted from the Swedish Perioperative Registry established that across a sample of 8,426 bariatric patients, 36.0% experienced a documented episode of nausea or vomiting explicitly within the immediate PACU setting.[5] Gender played a dominant role in susceptibility; female sex carried an adjusted odds ratio (aOR) of 2.21 (95% confidence interval [CI]: 1.96–2.50, P <.001), marking it as the single most powerful demographic predictor of early emesis.[5] Similarly, the prospective evaluation of 120 morbidly obese patients demonstrated a 32.0% PONV incidence in women versus a 15.0% incidence in men, alongside higher rates of severe, intractable nausea.[6] Younger patient cohorts displayed a markedly higher susceptibility, with registry data revealing an aOR of 0.85 per advancing decade of life (P <.001).[5] Severe postoperative pain (numerical rating scale > 5) increased the risk of PONV with an aOR of 1.56 (P <.001).[5] Surgically, laparoscopic sleeve gastrectomy was independently associated with a substantially higher frequency of early PONV compared to laparoscopic Roux-en-Y gastric bypass (aOR 1.69, P <.001), significantly lowering the neurological threshold for emesis.[5]
Intraoperative Anaesthetic Maintenance and Neuromuscular Blockade
Scoping reviews of clinical trials evaluating propofol-based TIVA against desflurane in sleeve gastrectomy patients reported substantial reductions in emesis incidence, lowering the raw incidence rate to 10.0% compared to 30.0% in desflurane cohorts, functioning mechanistically by inhibiting the release of serotonin in the area postrema.[3] Regarding neuromuscular blockade reversal, the clinical integration of sugammadex (allowing for the rapid, non-cholinergic reversal of rocuronium-induced block) was associated with significantly lower 30-day readmission rates compared to neostigmine.[8] Trials consistently demonstrated that sugammadex cohorts exhibited a significantly lower incidence of early nausea.[9]
The Opioid-free Anaesthesia Paradigm and Systemic Co-analgesics
The perioperative administration of systemic opioids remains the single most significant, yet entirely modifiable, pharmacological trigger for PONV, leading to severe gastric stasis.[1] Continuous intraoperative infusions of dexmedetomidine (0.2–0.5 mcg/kg/h) lowered nausea incidence to 3.0% when compared to remifentanil infusions (10.0%).[3] Systemic intravenous lidocaine infusions demonstrated reductions in overall opioid consumption and superior recovery profiles, though exact ideal-body-weight calculated dosing is required to avoid neurotoxicity.[3] Systematic reviews and network meta-analyses demonstrated that Opioid-Free Anaesthesia (OFA) was associated with improved postoperative quality of recovery scores[10] and significantly reduced postoperative morphine consumption in bariatric cohorts.[11,12] A single preoperative oral dose of pregabalin (150 mg) yielded an absolute risk reduction of 20.0% for PONV, lowering the incidence from 46.0% in placebo groups to 25.0%.[3] The scheduled administration of non-opioid simple analgesics, specifically intravenous ketorolac (30 mg), drastically reduced vomiting from 64.0% to 13.0%.[3]
Regional Anaesthesia as an Opioid-sparing Mechanical Adjunct
The integration of regional anaesthesia serves as a highly effective mechanical adjunct, designed to physically intercept somatic signals.[13] Studies utilising bilateral posterior Quadratus Lumborum blocks (QLB) have shown an ability to reduce nausea incidence from nearly 47.0% down to 13.0%.[13] Single-shot Ultrasound-guided Transabdominal Plane Block (UG-TAPB) reduces pain, opioid consumption and PONV, and is associated with faster recovery.[14] In addition to single-shot blocks, continuous transversus abdominis plane block techniques via catheter infusion have also been documented to provide effective ongoing postoperative analgesia following laparoscopic sleeve gastrectomy.[15] Furthermore, the External Oblique Intercostal Fascial Plane Block (EOIB) provided exceptional coverage for upper abdominal incisions characteristic of bariatric laparoscopy, with patients requiring rescue antiemetics at less than half the rate of unblocked control groups.[16]
Multimodal Pharmacological Prophylaxis
Because the act of emesis can be triggered by a vast multiplicity of redundant neurological pathways, ERAS guidelines firmly mandate the simultaneous administration of agents targeting at least three, and ideally four, distinct receptor classes.[3] A prospective evaluation comparing a formalised triple-component antiemetic regimen (dexamethasone, ondansetron, and droperidol) against dual therapy and standard TIVA controls exhibited an overall PONV incidence of only 26.0% in the triple cohort, a stark improvement over the 42.6% incidence observed with standard control care, and required subsequent rescue therapy in only 18.0% of cases.[17] Dexamethasone doses in the 4 to 10 mg range provide the most reliable antiemetic benefit, and its efficacy in reducing PONV is consistent regardless of whether it is administered before or after anaesthesia induction.[18]
To further suppress incidence rates, contemporary protocols are integrating NK-1 receptor antagonists, which fiercely block the binding of substance P.[2] Studies evaluating aprepitant demonstrate that a single preoperative oral dose of 80 mg significantly reduced total postoperative antiemetic requirements and hospital length of stay in sleeve gastrectomy patients.[19] A randomised trial focusing on metabolic syndrome assessed a highly potent triple therapy utilising ondansetron, dexamethasone, and aprepitant (40 mg), which reduced overall nausea incidence to 27.0%, compared to 60.0% with standard monotherapy.[20] When compounded with TIVA and non-pharmacological neuromodulation, the incidence rate plummeted to a study-low of 13.0%.[20] Subgroup meta-analyses also revealed that a 10 mg dose of olanzapine reduced the incidence of PONV by an average of 49% in surgical populations.[21,22] For breakthrough emesis that persists despite heavy prophylaxis, guidelines strictly mandate utilising a completely alternate pharmacological class to regain control of the emetic reflex.[3]
Dietary Composition and Non-pharmacological Interventions
A prospective trial explicitly comparing the early introduction of a high-protein, full-liquid diet against a standard clear liquid diet 4 hours postoperatively found a raw incidence of PONV of 89.3% in the high-protein group versus 78.6% in the clear liquid control group, showing no statistical benefit.[7] Importantly, 15 patients in the high-protein arm consumed exactly zero grams of protein due to nausea severity.[7] Central pharmacological blockade must be absolute before local gastrointestinal physiological interventions can be successfully initiated; forced early liquid protein frequently causes aversion and should never supersede aggressive antiemetic pharmacotherapy.[7] Conversely, trials evaluating P6 (Neiguan) point acupressure—which actively modulates parasympathetic vagal tone and alters the localised release of inhibitory neurotransmitters—integrated into a TIVA and triple-antiemetic pathway drove PONV incidence down to 13.0%, allowing patients to comfortably tolerate early oral intake at a mean of 12 hours with a significantly optimised hospital length of stay of 3.0 days.[2]
Discussion
The prevention of PONV in the context of metabolic and bariatric surgery remains a profoundly complex clinical challenge that cannot be adequately addressed by singular, reactive interventions. The synthesis of empirical data clearly illustrates that patients presenting with morbid obesity and metabolic syndrome possess distinct pathophysiological vulnerabilities that necessitate a universally applied, multimodal ERAS approach.[1]
The interpretation of the epidemiological and clinical trial data highlights the multifactorial aetiology of PONV in this cohort. The underlying mechanism for the stark gender discrepancy is largely attributed to fluctuating hormonal profiles, particularly cyclical variations in oestrogen and progesterone, which are known to sensitise the chemoreceptor trigger zone and alter dopaminergic and serotonergic receptor affinities in the central nervous system.[2] Furthermore, the specific surgical alterations inherent to bariatric procedures dictate the postoperative risk profile. During a sleeve gastrectomy, the virtually complete resection of the highly distensible gastric fundus drastically alters the production of the orexigenic hormone ghrelin. The creation of a narrow, tubular, high-pressure gastric remnant, combined with surgical trauma near vagal afferents, generates a relentless stream of afferent impulses to the medulla, explaining the significantly higher PONV rates compared to gastric bypass procedures.[2]
Compounding these anatomical vulnerabilities are distinct pharmacological challenges. Volatile inhalation anaesthetics are highly lipophilic and accumulate excessively within the massive adipose compartments of morbidly obese patients, leading to delayed clearance and an extended window of uninterrupted stimulation to the chemoreceptor trigger zone post-extubation.[3] Consequently, the routine use of volatile inhalation anaesthetics must be systematically abandoned in favour of TIVA utilising propofol infusions, which inherently modulate gamma-aminobutyric acid (GABA) receptors to actively inhibit serotonin release. Similarly, the clinical standard of care must aggressively pivot toward Opioid-Free Anaesthesia or maximal opioid-sparing techniques, as systemic opioids directly stimulate mu-opioid receptors in the area postrema and depress the enteric nervous system.[1] This objective requires the continuous use of systemic alpha-2 agonists, scheduled non-opioid analgesics, and structured regional fascial plane blocks (such as the TAP or EOIB) to intercept somatic nociceptive signals.
Because the act of emesis can be triggered by a vast multiplicity of redundant neurological pathways, single or dual-agent pharmacological antiemetic therapy is demonstrably insufficient. Institutional protocols must strictly mandate a minimum of three, and ideally four, antiemetic agents operating on completely distinct receptor classes simultaneously. The integration of a long-acting NK-1 receptor antagonist (aprepitant) with a 5-HT3 antagonist, a potent corticosteroid, and a D2 or H1 antagonist represents the optimal pharmacological shield.[3] Finally, the sequencing of gastrointestinal recovery must respect the hierarchy of physiology. Central pharmacological blockade must be absolute before local gastrointestinal physiological interventions can be successfully initiated; forced early liquid protein frequently causes aversion and is mechanistically futile if central emesis is not already thoroughly suppressed. In contrast, the adjunctive use of non-pharmacological neuromodulation, specifically P6 acupressure, serves as a highly synergistic modulator of autonomic vagal tone that demonstrably accelerates the patient’s ability to tolerate early oral hydration.[2]
It is important to acknowledge the limitations within the current body of literature. Many studies evaluating PONV in bariatric surgery are limited by small sample sizes, heterogeneous anaesthetic protocols, and the lack of standardised PONV outcome measures. Furthermore, while the efficacy of regional fascial plane blocks and novel opioid-sparing agents is well-documented, optimal dosing regimens specifically tailored to ideal or adjusted body weights in the morbidly obese population require further large-scale, dose-finding randomised controlled trials.
By systematically layering these precise interventions—accurately stratifying baseline demographic risk, rigorously controlling intraoperative neuropharmacology through TIVA and opioid-free techniques, and permanently saturating the medullary vomiting centres with multi-class antiemetics—clinicians can reliably and reproducibly reduce the incidence of postoperative nausea. This systemic optimisation not only alleviates profound, unnecessary patient suffering but directly safeguards delicate surgical anastomoses, expedites the resolution of metabolic syndrome, and ultimately fulfils the core, foundational objectives of the ERAS pathways.
Footnotes
Acknowledgements
The authors would like to acknowledge the Department of Anesthesiology and Resuscitation at the main campus of Tashkent State Medical University for their support in facilitating the clinical evaluations referenced in this review.
Declaration of conflicting interests
The authors declared no potential conflicts of interest with respect to the research, authorship and/or publication of this article.
Funding
The authors received no financial support for the research, authorship and/or publication of this article.
Institutional ethical committee approval number
Not applicable. This is a review and synthesis of previously published literature and registry data; no new human participants were directly recruited by the authors for this specific article.
Informed consent
Not applicable.
Credit author statement
SV conceptualised the review, conducted the literature search, extracted data, and drafted the initial manuscript.
SDN provided scientific supervision, validated the methodological approach, and critically revised the manuscript for important intellectual content.
Both authors read and approved the final manuscript.
Data availability statement
Not applicable. All data synthesised in this review are derived from the publicly available studies and registries cited in the reference list.
Use of artificial intelligence
The authors confirm that no artificial intelligence (AI) or AI-assisted technologies were used in the writing, data analysis or generation of this manuscript.